Ceftaroline in severe community-acquired pneumonia

ABSTRACT

Severe community-acquired pneumonia (SCAP) is associated with high mortality. Factor such as early adequate antibiotic therapy, delay in intensive care unit (ICU) care and pneumonia caused by resistant pathogens are associated with worseoutcomes in SCAP patients. Ceftaroline is a fifth-generationcephalosporin with bactericidal activity against Gram-positivepathogens (including methicillin-resistant Staphylococcus aureus [MRSA] and multidrug-resistant Streptococcus pneumoniae) and common Gram-negative organisms. The efficacy andsafety for the treatment of pneumonia was evaluated in threerandomized control trials were ceftaroline demonstrated superiority against ceftriaxone for the treatment of pneumoniain hospitalized patients with Pneumonia Severity Index (PSI)III – IV. (AU)